Pharmafile Logo

News and Press Releases

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression to phase 2 clinical trials in Malawi Demonstrates Recipharm’s agility and flexibility, completing full tech transfer, scale-up and process optimisation within three...

Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 15, 2025

Iksuda to present IKS014 Phase 1 data at ESMO

14 October 2025 -- Newcastle, UK -- Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

PlasmidFactory founder Dr. Martin Schleef honored with the NRW Innovation Award 2025

8 September 2025 -- Düsseldorf/Bielefeld, Germany -- The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored today in Düsseldorf with the Innovation Award 2025 of the...

Category: BioManufacturing, Other, Pharmaceutical
Posted: September 8, 2025

PlasmidFactory GmbH & Co. KG
info@plasmidfactory.com
Meisenstraße 96, D-33607 Bielefeld, Germany

Ryvu Therapeutics Announces Strategic Agreement to Support Clinical Trials for BioNTech’s Investigational Cancer Immunotherapies in Poland

Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland Ryvu will leverage its clinical network to...

Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 2, 2025

Ryvu Therapeutics
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

Iksuda Therapeutics receives FDA IND clearance for IKS014

FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 1, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Sanner starts manufacturing in Greensboro, USA

18 June 2025 -- North Carolina, US -- Sanner has officially launched manufacturing operations in Greensboro, North Carolina. The new facility is dedicated to producing critical injection-molded components for medical...

Category: Logistics, Manufacturing and Packing, Other, Pharmaceutical, Pharmaceutical Contractors
Posted: June 18, 2025

Sanner
info@sanner-group.com
Schillerstrasse 76 64625 Bensheim

CARBOGEN AMCIS Accelerates Manufacturing Capacity with CHF 25.5 Million Co-Investment at Swiss Sites

4 June 2025 -- Bubendorf, Switzerland -- CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce a strategic co-investment of more...

Category: Logistics, Manufacturing and Packing, Pharmaceutical
Posted: June 4, 2025

CARBOGEN AMCIS
info@carbogen-amcis.com
Hauptstrasse 171 CH-4416 Bubendorf Switzerland

Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025

• HDP-101 demonstrated complete response in one female patient from cohort 5• R&D Webinar to be hosted on 17 June 2025. 15 May 2025 -- Ladenburg, Germany -- Heidelberg Pharma...

Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 15, 2025

Heidelberg Pharma
info@hdpharma.com
Gregor-Mendel-Straße 22 68526 Ladenburg Deutschland

Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers

Integrated solution with self-service capabilities simplifies trial experience for all 13 May 2025 -- California, US -- Medable Inc., a leading provider of clinical development and eCOA technology, today announced...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

iOnctura commences randomized Phase I/II study in non-small cell lung cancer

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025

iOnctura
enquiries@ionctura.com
Campus Biotech Innovation Park Avenue Sécheron 15
 1202 Genève
 Switzerland

Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025

Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 30, 2025

Domain Therapeutics
contact@domaintherapeutics.com
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France

Iksuda to present growing ADC pipeline at AACR

Introduces the ProAlk payload series to address the growing challenge of ADC sequencing IKS04 to enter clinical development for gastrointestinal cancers by end of 2025 PermaLink offers stable and scalable...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 25, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies

In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025

Mosaic Therapeutics
info@mosaic-tx.com
Mosaic Therapeutics Wellcome Genome Campus Cambridge CB10 1DR

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology 23 April 2025 -- Colorado,...

Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Biodesix
919 W Dillon Rd, Louisville, CO 80027

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

23 April 2025 -- Ingelheim, Germany and Amsterdam, the Netherlands -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein